Louise Kooij - Sep 9, 2025 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Role
Chief Accounting Officer
Signature
/s/ Louise Kooij
Stock symbol
NAMS
Transactions as of
Sep 9, 2025
Transactions value $
-$2,374,017
Form type
4
Date filed
9/10/2025, 05:39 PM
Previous filing
Sep 5, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kooij Louise Frederika Chief Accounting Officer C/O NEWAMSTERDAM PHARMA COMPANY N.V., GOOIMEER 2-35, NAARDEN, NETHERLANDS /s/ Louise Kooij 2025-09-10 0002004379

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NAMS Ordinary Shares Options Exercise $1.5M +150K +1000% $10.00 165K Sep 9, 2025 Direct
transaction NAMS Ordinary Shares Sale -$1.34M -53.1K -32.18% $25.31 112K Sep 9, 2025 Direct F1
transaction NAMS Ordinary Shares Sale -$2.53M -96.9K -86.59% $26.11 15K Sep 9, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NAMS Option (right to buy) Options Exercise $0 -150K -34.88% $0.00 280K Sep 9, 2025 Ordinary Shares 150K $10.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.87 to $25.86 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.87 to $26.28 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F3 The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 1, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date.